B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Benzinga Newsdesk www.benzinga.com Positive 62.1%

Neg 0% Neu 0% Pos 62.1%

B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.